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Adenocarcinoma of the prostate is now the second leading cause
of male death from malignant disease in the US and in Europe
(Foster, 1990; Geller, 1995). In common with other malignant
diseases, metastasized prostate cancer cells are invariably resistant
to all currently available therapies (Foster et al, 1992). This glaring
clinical fact has lent fresh impetus to the need for better under-
standing of mechanisms underlying metastatic behaviour. Progress
on this front has been heightened recently by reproducible models
of inducing metastases through transfection of fragmented DNA
from malignant tumours into non-metastatic cells (Ke et al, 1998).
Identification and characterization of genes involved in the
metastatic phenotype of prostate cancer cells through these model
systems hold the promise of propelling much needed advance-
ments in therapy.
Whilst the metastatic cascade may involve complicated multiple
genetic changes, angiogenesis is an essential common mechanism
for the development and the formation of metastasis in solid
tumours. This makes anti-angiogenic therapy an attractive and
promising treatment for cancer (Battegay, 1995). Angiogenesis is
regulated by a number of both stimulating and inhibiting angio-
genic factors. VEGF is one of the most potent factors for
stimulating angiogenesis (Stephan and Brock 1996). Although
VEGF has been previously detected in prostate cancer (Jackson et
al, 1997; Ferrer et al, 1998; Haggstrom et al, 1998), these observa-
tions were made in tissue specimens. Thus, it is not clear whether
the detected VEGF is made by tumour cells themselves or by their
adjacent cells. This is important because VEGF has been reported
to be produced by tumour-associated cells like endothelial cells,
infiltrated T-cells and macrophages, as well as by surrounding
stromal cells (Fukumura et al, 1998). Furthermore, it is not
completely understood whether it is the VEGF or other angiogenic
factors, such as basic fibroblast growth factor (FGF) and inter-
leukin-8, which have also been detected in some prostate tissues
(Deshmukh et al, 1997; Haggstrom et al, 1998), that are respon-
sible for neovascularization required for the malignant progression
of prostate cancer cells. There is no experimental data to show
whether the VEGF produced by a human prostate carcinoma cell
line (Ferrer et al, 1997) is capable to induce angiogenesis.
In order to make a quantitative assessment of differential
expression of VEGF between the benign and the malignant
prostate epithelial cells, and particularly, to test the angiogenic
ability of the VEGF produced by prostate carcinoma cells, we
have performed the present study in well-characterized cell culture
system. We have first measured the level of VEGF expression in a
wide range of different human and rat prostate cell lines with
either benign or malignant properties to determine whether the
elevated expression of VEGF is associated with the increased
malignant characteristics of the cells. Then, we have examined
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whether the ability of producing high level of VEGF can be trans-
ferred as the transformation of the metastatic capability of the cells
by comparing the VEGF levels in three metastatic variants with
that in their parental benign cells. These metastatic variants have
been generated by transfection of a benign cell line with genomic
DNA extracted from prostate carcinoma cells (Ke et al, 1998).
Finally, we employed an in vivo angiogenesis assay to determine
whether the VEGF produced by the malignant cells can induce
new blood vessel formation.
MATERIALS AND METHODS
Cell lines and culture conditions
Three groups of 13 well-characterized benign and malignant cell
lines were used in this study. The first group is the four human
prostate cell lines which include one benign cell line and three
malignant cell lines. The benign cell line PNT-2 was derived from
human prostate epithelial cells (Cussenot et al, 1991, 1994;
Berthon et al, 1995). One of the malignant cell line LNCap was
derived from prostate carcinoma (Horoszewicz et al, 1983), and
other two malignant cell lines, PC-3 and DU145, were derived
from malignant metastases of prostate cancer in rib and brain
respectively (Kaighn et al, 1978; Stone et al, 1978). The second
group of cell lines examined in this study was the five biologically
distinct sublines from the Dunning R3327 rat prostate carcinoma
model (Isaacs et al, 1986). The G cell line is the least malignant
cell line and it can induce only less than 5% of animals with metas-
tasis when introduced into the syngeneic rats. The second cell line
in this group was the weakly metastatic cell line AT-2, which can
induce up to 20% of animals with metastasis. The remaining three
cell lines in this group were the highly metastatic cell lines AT-3,
MAT-Lu and AT-6.1, which can induce more than 75% of animals
with metastasis. The last group of cell lines used in this study was
the benign rat cell line Rama 37 (Dunnington et al, 1983) and its
three malignant metastatic sublines established by transfecting the
Rama 37 cells with DNA extracted from prostate carcinoma cells
(Ke et al, 1998). The human and rat cell lines were grown as
monolayer cultures in RPMI-1640 (human cells) and Dulbecco’s
modified Eagles medium (DMEM) (rat cells) media, supple-
mented with 10% (v/v) fetal calf serum, hydrocortisone (5 ng
ml–1), penicillin (100 units ml–1) and streptomycin (100 mg ml–1),
with either testosterone (5 ng ml–1, for human and rat prostate
cells), or insulin (5 ng ml–1, for Rama 37 and its derivative lines).
cDNA probes
The human VEGF probe used in this study was a 655-bp cDNA
fragment (a gift from ZENECA Pharmaceuticals). Both glycer-
aldehyde 3-phosphate dehydrogenase (GAPDH) and actin probes
were purchased from CLONTECH Laboratory (UK). The rat
VEGF probe was a 601-bp cDNA fragment prepared by reverse
transcription polymerase chain reaction (RT-PCR), using 100 ng
mRNA extracted from AT-3 cells as template, and using a pair of
rat VEGF specific primers (sense: 5¢-AACCATGAACTTTCT-
GCTCTC-3¢; antisense: 5¢-GGTGAGAGGTCTAGTTCCCGA-
3¢). The sequence of the amplified rat VEGF probe was confirmed
by nucleotide sequencing analysis using a DNA sequencing kit
(Amersham Life Science). Each probe containing 25 ng cDNA
was labelled with [a-32P]dCTP to a specific radioactivity of
0.5–1.0 ´ 109 dpm  mg–1 cDNA using a random promed DNA
labelling kit (Boehringer Mannheim GmbH, Germany).
Detection of VEGF mRNA
The expression of VEGF mRNA in different cell lines were detected
by Northern blotting. Total RNA was isolated from each cell line by
lysing the cells with 4 M guanidine isothiocyanate and purified by
CsCl gradient centrifugation. The mRNA was further purified from
total cellular RNA using Oligotex mRNA Kit (Qiagen Ltd, UK).
Northern blotting was performed as described previously (Alwine et
al, 1977). Briefly, total RNA (10 mg) was separated by elec-
trophoresis in a 0.8% denaturing formaldehyde-agarose gels. The
separated RNAs were transferred onto a nylon Hybond-N membrane
(Amersham Inc, UK) overnight by capillary elution. After the
membranes were pre-hybridized at 42°C for 3–4 h in the solution
containing 50% formamide, 5% Denhardt’s, 6 ´sodium–saline phos-
phate–EDTA (SSPE), 0.5% sodium dodecyl sulphate (SDS) and 100
mg ml–1 of denatured sonicated salmon sperm DNA, the membranes
were hybridized overnight under the same condition with cDNA
probes. The probed membranes were subjected to stringent washes
and exposed to Kodak XAR-5 films. The intensity of each band
appearing on the film was scanned and analysed with Phoretix 1D-
advanced vs 3.1 software. The loading artifact was normalized with
the constitutively expressed GAPDH or actin mRNAs.
Slot blotting was used for quantitative analysis of VEGF mRNA
expressed in four human prostate cell lines. Increasing amounts of
mRNA from 0.05 to 1.6 mg were loaded onto a nylon Hybond-N
membrane using a slot-blot apparatus (Bio-Rad, Hercule, CA,
USA). After fixed by ultraviolet light, the membrane was pre- and
hybridized with the radioactively labelled human VEGF probe and
GAPDH probe respectively, washed and subjected to autoradiog-
raphy. Intensities of each band were scanned as described above for
Northern blotting. The best-fit straight lines of plots of peak area
against the amount of RNA per slot over the linear part of the plot
were calculated by linear regression. Any loading artefacts were
normalized with the consititutively expressed GAPDH mRNA.
Detection of VEGF protein
In a 96-well microtitre plate, 100 ml of mouse anti-hVEGF mono-
clonal antibody (1 mg ml–1 in 50 mM of sodium carbonate, pH 9.6)
was coated overnight at 4°C. The plate was then blocked with
blocking buffer (2% bovine serum albumin (BSA) in phosphate-
buttered saline (PBS)) for 2 h at room temperature (RT).
Conditioned medium (serum-free medium used for culturing cells
for 48 h) or rhVEGF standard (R & D System) was added and
incubation continued for another 2 h at RT. Goat anti-hVEGF
polyclonal antibody (R & D System) was added (100 ml of 
1 mg ml–1) to each well after washing the plate with the washing
buffer (0.1% Tween-20 in PBS) and then incubated at RT for 2 h.
The detection antibody, a peroxidase-labelled rabbit anti-goat IgG
(Zymed, USA, 61-1620), was added and reaction continued for
another 2 h at RT. The plate was washed again with washing
buffer, the substrate solution (0.04% o-phenylenediamine dihy-
drochloride in PBS plus 0.4 ml l–1 of 30% hydrogen peroxide) was
used to develop colour. The colour was quantitated with TiterteK
Multiskan PLUS (Flow Laboratories, Finland) at 492 nm. The
limit of sensitivity of this assay was 0.4 ng ml–1.
Analysis of isoforms of VEGF gene transcripts
RT-PCR analysis was performed to study potential splicing vari-
ants of the VEGF gene in human cell lines. The first strand of1696 HJ Chen et al
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cDNA was synthesized from the poly-adenosine (poly-A) end of
the mRNA (100 ng) extracted from both PNT-2 and DU145 cells
using the First Strand cDNA Synthesis Kit for RT-PCR
(Boehringer). The reverse transcription products (2.5 ml) were
amplified by PCR using a primer pair allowing to amplify all
possible VEGF isoforms (sense: 5¢-TCGGGCCTCCGAAAC-
CATGC-3¢; antisense: 5¢-CCTGGTGAGAGATCTGGTTC-3¢).
The amplified PCR products were subjected to electrophoresis and
visualized by ethidium bromide staining. The products were also
transformed onto a nylon membrane (Hybond N, Amersham) and
hybridized with the human VEGF probe. To confirm the sequences
of products amplified by PCR being VEGF isoforms, the PCR
products were cloned into pBlueScript plasmid, and their
sequences were determined by nucleotide sequencing analysis
using a DNA Sequencing Kit (Amersham Life Science).
Chick chorioallantoic membrane assay
The angiogenic activity of the conditioned media from both the
malignant DU145 and the benign PNT-2 cells were determined by
the CAM assay, as described previously (West et al, 1985). Both
control medium (serum-free medium without cells) and condi-
tioned medium were concentrated tenfold by centrifugal ultra-
filtration (3 kDa cut-off). The rhVEGF 121 protein (positive
control) was dissolved in Dulbecco’s PBS at a concentration of
100 ng ml–1. For application to the eggs, a 40 ml aliquot of each
sample was mixed with 50 ml of 1% sterile methylcellulose (M-
0512, 4000 centipoises, Sigma) and 1 ml PBS or 1 ml anti-hVEGF
neutralizing antibody (MAB293, R & D Systems Ltd) at a 50-fold
excess concentration to rhVEGF 121. This mixture (10 ml) was
then applied on to a 2 mm diameter ‘Teflon’ column and dried,
under sterile conditions, to give a clear disc. The samples were
applied on to the CAM on day 10, when vessel growth ostensibly
finished. The angiogenic reaction was determined on day 14. The
angiogenic reaction was scored as: 0 – negative; 0.5 – change in
vessel architecture but not directed to the point of sample applica-
tion; 1 – partial spokewheel (1/3 of circumference exhibits direc-
tional angiogenesis); 2 – spokewheel, 3 or up–strong and fully
spokewheel. This approach enabled calculation of accumulated
responses for the test samples in each group. For photography, the
membranes were fixed in situ with ice-cold 4% paraformaldehyde-
PBS that was injected both from above and below the membrane.
Membranes were excised, placed on a fresh microscope slide and
photographed under a Leitz binocular dissecting microscope and
indirect fibreoptic illumination. Statistical analysis was performed
using the Mann–Whitney U-test.
RESULTS
VEGF mRNA level in the benign and malignant cell
lines
Northern and slot blotting was used to detect the level of VEGF
mRNA in human benign and malignant cell lines. The radio-
actively labelled human VEGF probe detected one VEGF band at
a molecular size of about 3.9 kilobases (kb) in all the four cell lines
examined (Figure 1A), consistent with the expected size of VEGF
mRNA (Tischer et al, 1991; Shima et al, 1995). Scanning the
intensities of the bands showed that the lowest level of VEGF
mRNA was detected in the benign cell line PNT-2, this level was
increased by 2.7-fold in the malignant cell line LNCap. Further
increases of 4.3-fold and 8.5-fold were detected in the malignant
metastasis-derived cell lines PC-3 and DU145 respectively. More
accurate measurements of the VEGF mRNA level by slot-blotting
detected similar differences between the benign and the malignant
cell lines as those detected by Northern blotting. Relative to the
lowest level expressed in the PNT-2 cell line, the level of VEGF
mRNA in LNCap, PC-3 and DU145 cell lines was increased by
2.9 ± 0.5, 4.9 ± 0.7 and 10 ± 0.95-fold respectively (Figure 1B).
The levels of VEGF mRNA in the five Dunning R3327 rat
carcinoma cell lines were measured using Northern blotting. As
shown in Figure 2A, the expression of VEGF in these cell lines
was elevated in direct correlation with the increase in their
metastatic characteristics. The G-cell line, which has the lowest
metastatic potential, expressed the lowest level of VEGF mRNA.
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Figure 1 Detection of VEGF transcripts in benign and malignant human
prostate cell lines. (A) Northern blotting. Total RNA (about 10 mg) from
LNCap (1), DU145 (2), PC-3 (3) and PNT-2 (4) were subjected to
electrophoresis in a 0.8% agarose gel. The separated RNAs were transferred
onto a nylon membrane and hybridized with radioactively labelled human
VEGF cDNA probe. The washed membrane was exposed to a Kodak XAR-5
film for 3 days. The same membrane was re-hybridized with a radioactively
labelled GAPDH cDNA probe and the hybridized band visualized by
exposure to Kodak film for 3 h. Molecular size of RNA markers are shown in
kilobases (kb). (B) Quantification of the relative levels of VEGF mRNA. The
relative hybridization of the VEGF transcripts to the VEGF cDNA probe was
determined by measuring the intensity of autoradiographic images of the
Northern and Slot-blots. Black bars represent the mean and standard
deviation (s.d.) of three measurements by three separate slot-blot analyses.
The shaded bars represent single measurement by Northern blottingThe VEGF expression level was 2.9-fold higher in the weakly
metastatic AT-2 cells than that in the G-cells. In the three highly
metastatic cell lines, AT-3, MAT-Lu and AT-6.1, the expression of
VEGF mRNA was 6-, 3.5- and 7.8-fold respectively higher than
that expressed in the G-cells.
The levels of VEGF mRNA in the benign rat Rama 37 cell line
and its three malignant metastatic sublines were shown in Figure
2B. The lowest level was detected in the benign Rama 37 cells.
Comparing with their parental benign Rama 37 cells, the amount
of VEGF mRNA expressed in the RMP2c-Lu, RMP2c-H and
RMP2b-Lu was increased by 2.5-, 4.5- and 3.4-fold respectively.
Detection of the VEGF isoforms in human benign and
malignant cell lines
RT-PCR performed in the benign PNT-2 and the malignant DU145
cells (Figure 3A) showed that two VEGF mRNA isoforms coding
for VEGF 121 and VEGF 165 proteins, respectively, were tran-
scribed in both the benign (lane 1) and the malignant (lane 2) cell
lines. In addition to these two smaller transcripts, another band
with a molecular size larger than the VEGF 165 transcript was
detected in the malignant DU145 cells, but not in the benign PNT-
2 cells (Figure 3B). Nucleotide sequence analysis revealed that the
smallest band was VEGF 121, the middle-sized band was VEGF-
165 and the largest band was VEGF 189.
VEGF protein secreted by human benign and malignant
cell lines
At the protein level (Figure 4), the difference in VEGF synthesis
between the benign and the malignant cell lines was observed. The
VEGF protein secreted by the benign PNT-2 cells (8 ´ 105 cells)
was 1.3 ± 0.06 ng per 48 h. In contrast, the amounts of VEGF
protein secreted in malignant LNCap cells and the malignant
metastasis-derived PC-3 cells and DU145 cells were 2.7 ± 0.03 ng,
3.1  ± 0.09 ng and 7.9 ± 0.09 ng respectively, under the same
culture condition.
Angiogenic activity of the VEGF protein produced by
human benign and malignant cell lines
Conditioned media from a benign (PNT-2) and a malignant cell line
(DU 145) cell line were collected for CAM assay, using rhVEGF
121 as the positive control. As shown in Figure 5A and 5D, the
rhVEGF 121 induced a strong angiogenic response which was
neutralized by a 50-fold excess of VEGF neutralizing antibody. The
Increased expression of VEGF facilitates the metastasis of prostate cancer 1697
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Figure 2 Detection of VEGF transcripts in the Dunning R3327 rat cell lines
(A), and Rama 37 and its derivative cell lines (B) by Northern blotting. Total
RNA (about 10 mg) from each cell line was subjected to electrophoresis in a
0.8% agarose gel. The separated RNAs were transferred onto a nylon
membrane and hybridized with radioactively labelled rat VEGF cDNA probe.
The washed membrane was exposed to a Kodak XAR-5 film for 5 days. The
same membrane was re-hybridized with a radioactively labelled rat actin
cDNA probe and visualized by exposure to Kodak film overnight. The relative
hybridization was determined by measuring the intensities of the bands with
densitometry scanning
Figure 3 Detection of the isoforms of VEGF in benign and malignant
human cell lines. (A) Detection by RT-PCR. The first-strand cDNA was
synthesized from 100 ng mRNA extracted from PNT-2 (1) and DU145 cells
(2) respectively. The amplified PCR products were electrophoresed in a 0.8%
agarose gel. VEGF 165 (3) and VEGF 121 (4) DNA fragments were included
as controls. Lane 5 is the DNA size markers. (B) Southern-blotting analysis
of the VEGF isoforms. The RT-PCR products amplified from the cDNA of
PNT-2 and DU145 cells were electrophoresed in an agarose gel, transferred
onto a nylon membrane and hybridized with radioreactively labelled human
VEGF cDNA probe. The radioactivity was visualized by radioautography
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Bresponse to conditioned medium from PNT-2 cells was weak
(Figure 5C), but conditioned medium from DU145 cells showed a
moderate angiogenic response (Figure 5B). The VEGF antibody
completely neutralized the angiogenic effect of the conditioned
medium from malignant DU145 cells (Figure 5E). However, there
was no effect of the same antibody on the weakly angiogenesis
induced by the conditioned medium from benign PNT-2 cells
(Figure 5F). Quantitative analysis of angiogenesis induced by the
above different additions was performed using the criteria
described in Materials and Methods and shown in Figure 5G.
DISCUSSION
In this study, we have investigated the expression of VEGF in
several benign and malignant cell lines from both human and rat
cell models. Among the four human prostate cell lines, the weakly
metastatic cell line LNCap expressed nearly three times the level
of VEGF mRNA and twice the level of VEGF protein as that
expressed in the benign PNT-2 cells. In the two malignant metas-
tasis-derived cell lines, PC-3 and DU145, the expression of VEGF
mRNA was fourfold and tenfold respectively higher than that
expressed by the benign PNT-2 cells. These results suggest that the
enhanced expression of the VEGF gene is associated with the
malignant characteristics of human prostate cells, which is consis-
tent with previous published works (Ferrer et al, 1997; Connolly
and Rose 1998; Balbay et al, 1999; Melnyk et al, 1999).
A similar pattern of VEGF expression was also detected in the
rat cell lines used. In the weakly metastatic cell line AT-2, the
expression level of VEGF was nearly three times of that detected
in the least malignant G-cells; whereas the expression of VEGF in
the three highly metastatic cell lines AT-3, MAT-Lu and AT6.1 was
3.5- to 7.8-fold higher than that detected in the G-cells. These
results not only show that the high level expression of VEGF was
associated with the malignant phenotype of the prostatic epithelial
cells, but that the elevated expression of VEGF was closely associ-
ated with the increasing metastatic characteristics of the malignant
cells. As such, it is possible that VEGF may play an important role
in the malignant dissemination of prostate cancer cells.
Higher levels of VEGF in serum or plasma have been evaluated
as a predictor of outcome in patients with several malignant
diseases (Dirix et al, 1996; Crew et al, 1997; Salven et al, 1997;
Kraft et al, 1999; Molica et al, 1999). Recently, it has also been
suggested that the patients with metastatic prostate cancer have
higher plasma VEGF levels than those with localized disease or
healthy controls (Duque et al, 1999). Over-expression of VEGF by
malignant prostate carcinoma cells as shown by our investigation
and other reports (Ferrer et al, 1997; Connolly and Rose 1998;
Balbay et al, 1999; Melnyk et al, 1999) may contribute to the
elevated serum or plasma VEGF levels. More studies are needed
to confirm the predictive utility of the VEGF produced by malig-
nant prostate cells themselves.
In this study, we also examined the isoform patterns of VEGF
mRNA expressed by the cells with either benign or malignant
characteristics. Five different isoforms of VEGF transcripts
encoding polypeptides of 206, 189, 165, 145 and 121 amino acids
have been reported to be expressed in human cells (Houck et al,
1991; Tischer et al, 1991; Poltorak et al, 1997). Our results
revealed that VEGF 121 and 165 were the predominant VEGF
isoforms expressed by both benign and malignant human cell
lines. Interestingly, an additional transcript representing VEGF
189 isoform was only detected in the malignant cells, but not in the
benign cells. Recently, it was reported that colon cancer patients
with liver metastasis showed significantly higher levels of VEGF
189 mRNA than those without liver metastasis. The expression of
VEGF 189 isoform may be correlated with metastasis and a poorer
prognosis in colon cancer (Tokunaga et al, 1998). Combining this
finding with our observation, the absence of VEGF isoform 189 in
the benign PNT-2 cells may indicate that the increasing malignant
characteristics of prostate carcinoma cells may not only be associ-
ated with the elevated level of VEGF, but also correlated with the
expressed isoform patterns of VEGF gene. Further studies are
needed to establish whether the expression of a particular VEGF
isoform (e.g. VEGF 189) in malignant cells could be used clini-
cally to predict the stage of prostate carcinoma or the outcome of
patients with the disease.
Results from CAM assay demonstrated that the process of new
blood vessel formation was markedly stimulated by conditioned
medium from malignant DU145 cells, and this activity was
completely abolished by a neutralizing anti-hVEGF antibody.
Conversely, the weaker angiogenic activity induced by condi-
tioned medium from the benign PNT-2 cells was not inhibited by
the addition of the same neutralizing antibody. These results indi-
cated that the moderate angiogenic activity of malignant cells was
caused by the highly expressed VEGF protein whereas the low
angiogenic activity observed in the conditioned medium from
benign cells was caused by factors other than VEGF. This suggests
that not only the level of VEGF was greatly increased in the malig-
nant cells, but also the VEGF produced by the malignant cells
played a greater, or pivotal role in stimulating angiogenesis than
that produced by the benign cells. Thus, the elevated amount of
angiogenically active VEGF derived from malignant cells may be
responsible for the development of neovascularization in the
microenvironment of secondary tumours. Since angiogenic
activity can facilitate the process of cell metastasis (Liotta et al,
1991; Weidner, 1995), it is possible that the metastatic capability
of the malignant prostate cells may have been greatly facilitated by 
the high expression of biologically active VEGF, with its strong
angiogenesis-promoting activity.
1698 HJ Chen et al
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Figure 4 Detection of VEGF proteins secreted by human benign and
malignant cell lines with ELISA. The level of VEGF in conditioned media from
the benign and the malignant cell lines were measured using ELISA. The
amount of VEGF protein was calculated by relating to the standard curve
established from serial dilutions of rhVEGF protein. Bars represent the mean
and standard deviation (s.d.) of six measurements from two separate
experimentsIncreased expression of VEGF facilitates the metastasis of prostate cancer 1699
British Journal of Cancer  (2000)  82(10), 1694–1701  © 2000 Cancer Research Campaign
AD
BE
CF
Figure 5 Detection of angiogenic activity by CAM assay. Angiogenesis in chick embryos was induced by rhVEGF 121 protein (A), the conditioned media from
the malignant metastasis-derived cell line DU145, (B) and the benign cell line PNT-2 (C). The inhibition of the angiogenic activity induced by rhVEGF 121 (D),
and conditioned medium from the malignant DU145 cells (E) was achieved by the VEGF neutralizing antibody. However, the same antibody did not affect the
weak angiogenic activity induced by the conditioned medium from the benign PNT-2 cells (F). All pictures are ´8 magnification. (G) a plot of CAM score of the
angiogenic activities in the presence of the different additions, and ‘+’ indicates the medium plus the neutralizing anti-hVEGF antibody. *Represents P < 0.05 vs
control and **represents P < 0.05 vs sample without the neutralizing antibody (Mann–Witney U-test)1700 HJ Chen et al
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To further test this hypothesis, we compared the expression
levels of VEGF mRNA between the benign Rama 37 cell line
(Dunnington et al, 1983) and its three metastatic variants, RMP2b-
Lu, RMP2c-Lu and RMP2c-H. Northern blotting showed that the
level of VEGF mRNA expressed in three metastatic cell lines were
2.6- to 4.8-fold higher than that expressed by their benign parental
Rama 37 cells. This result indicated that both the capability of
synthesizing high level VEGF and of disseminating to secondary
sites, which are possessed by the DNA donor cells AT6.1, had been
transformed into the DNA recipient cells Rama 37 through DNA
transfection. Further studies determining how the metastasis-
promoting DNA from the donor cells up-regulates VEGF expres-
sion in the recipient cells could provide much needed insight into
the molecular mechanism for the initiation and development of
malignant progression in prostate and other malignant diseases.
Although we have generally found that the elevated expression
of VEGF was closely associated with the increased metastatic
potential of the cells, we observed a possible discrepancy between
the malignant PC-3 and DU145 cell lines. It has been demon-
strated that the metastatic potential of PC-3 is slightly higher than
that of DU145 cells (Ke et al, unpublished observation). However,
in this work, the VEGF expression in DU145 was higher than that
in PC-3, although both were much higher (ten- and nearly fourfold
respectively) than that expressed by the benign PNT-2 cells. Since
PC-3 was established from a rib metastasis (Kaighn et al, 1979)
and DU145 was established from a brain metastasis (Stone et al,
1978), the different growing microenvironments of the secondary
tumours may have different requirements on the speed and degree
of vascularization. More importantly, metastasis is the conse-
quence of complicated molecular and genetic changes occurring 
in malignant cells. Whilst elevated expression of VEGF may be
important in promoting and maintaining metastasis development,
there may be more gene(s) involved in the initiation of malignant
dissemination. Our recent work (accepted for publication by
Cancer Research.) suggested that it is likely that the collective
effect of several metastasis-related genes, rather than VEGF alone,
determined the behaviour of the individual malignant cells.
Although the over-expression of VEGF is important and seems to
be essential for metastasis, the metastatic capability of the cells is
not completely determined by VEGF alone. Thus, the discrepancy
in VEGF expression observed between PC-3 and DU145 cells may
reflect the differences in molecular complexities which caused
the spread of the two separate clones to different secondary sites in
the body.
In conclusion, we have now provided evidence to support a role
for the angiogenically active VEGF derived from the malignant
cells as a metastasis-associated gene in prostate cancer. Its rele-
vance in the relative comparison between prostate cell lines of
differing metastatic potential was further emphasized in the rat
metastatic model of prostate cancer. VEGF ligand secreted 
by malignant prostate cells may be a key factor in inducing 
angiogenesis through paracrine mechanisms on the surface of
endothelial cells and in so doing, greatly facilitate the process 
and development of metastasis.
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